Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morgan Stanley

Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) elevates climate action goals with commitments for net zero greenhouse gas emissions aligned with the Paris Agreement, commits to verified Science Based Targets, signs the Business Ambition for 1.5 degree and joins the United Nations campaign Race to Zero.

Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050

Merck

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge genetic mutations involved in homologous recombination deficiency (HRD) and identify best responders to PARP inhibitors. Illumina first announced the partnership in January at the JP Morgan Healthcare Conference.

Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay

SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD).

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

The gene-sequencing giant sees a huge opportunity in diagnostics.

Why Illumina Wants Grail Back So Badly

Beam Therapeutics

Editas Medicine

Intellia Therapeutics

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Revolution, the Proteomic Revolution Is Coming appeared first on InvestorPlace.

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Two Republican lawmakers on Thursday questioned the Federal Trade Commission's efforts to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging the regulator was not following a normal path in its work.

U.S. lawmakers question FTC's efforts to stop Illumina's deal for Grail

Guidewire Software

Synopsys

Former Vice President Al Gore (Trades, Portfolio), leader of Generation Investment Management, and Jerome Dodson (Trades, Portfolio)'s Parnassus Investments may take slightly different approaches to identifying good value opportunities, but they are both known for their commitment to being socially responsible investors. As such, they have several holdings in common.

3 Stocks These ESG Gurus Agree On

Feds tell judge that the combined companies will unfairly monopolize the market for blood screening that can detect multiple cancers.

Will Illumina's Purchase of Grail Kill Cancer-Test Competition?

According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.

Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges

The U.S. Federal Trade Commission on Tuesday said it seeks to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging it would harm innovation and boost prices.

FTC urges judge to unwind $7.1 billion Illumina-Grail merger

Align Technology

Crocs

Electronic Arts

Match Group

Shopify

Upstart Holdings

These growth stocks could boost growth portfolios in the coming quarters The post 7 Great Growth Stocks to Buy Now to Build Your Portfolio appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

7 Great Growth Stocks to Buy Now to Build Your Portfolio

Opening arguments begin Tuesday in the government's antitrust case against Illumina's acquisition of cancer-screening pioneer Grail.

FTC Case Against Illumina's Grail Acquisition Begins Today. What to Know.

The stock price of Illumina, a gene sequencing company, reached an all-time high of $524 earlier this month before a recent sell-off drove the stock price down 6% to its current level of around $487. ILMN stock has fallen 6% over the last five days, after the company announced the completion of.

Will Illumina Stock Rebound After A 6% Fall Last Week?

Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.

Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion

U.S. life sciences company Illumina could face a hefty fine for jumping the gun by completing its $8 billion cash-and-stock takeover of cancer detection test maker Grail without first securing EU antitrust approval.

Illumina in EU antitrust sights over premature $8 billion Grail deal

The genetic-testing company just blatantly defied its regulators.

Why Illumina Stock Just Dropped 10%

Shares of Illumina Inc. ILMN, -9.86% tumbled 9.8% in afternoon trading Thursday, enough to pace the S&P 500's SPX, +0.01% decliners, after the life sciences tools disclosed that it is likely to be fined for completing its acquisition of GRAIL Inc. while the European Commission was still reviewing the merger. The stock was headed for the biggest one-day drop since the 10.9% plunge on Aug. 7, 2020 after a disappointing earnings report.

Illumina's stock suffering biggest selloff in a year after warning of fines for closing GRAIL merger too soon

In defiance of FTC and EU scrutiny, Illumina Inc (NASDAQ: ILMN) went ahead to complete its $8 billion acquisition of Grail. The finalization of the buyout comes as the FTC sued to block the move in March and the European Commission continues its ongoing regulatory review.

Illumina Completes Grail Buyout Despite Uncertainty In Regulatory Process

Illumina Inc has completed its $7.1 billion acquisition of cancer detection test maker Grail Inc, it said on Wednesday amid challenges posed by the U.S. Federal Trade Commission and the European Union antitrust regulators.

Illumina closes $7.1 billion deal for cancer test maker Grail amid regulatory hurdles

SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review. Illumina, the global leader in DNA sequencing, first announced its intention to acquire GRAIL nearly a year ago, reuniting Illumina with GRAIL four years after it was spun off.

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

In just over three months, shares of gene-sequencing leader Illumina Inc. ( ILMN , Financial) have climbed nearly 40% to about $517, a price some analysts think doesn't leave the company much headroom.

Illumina Bumping Against Top of Analysts' Price Estimates

According to CEO Francis deSouza, the genetic life-sciences company is "firing on all cylinders."

Illumina Delivers a Beat and a Raise in Q2

The European Commission has temporarily suspended the provisional deadline for its investigation into Illumina Inc's (NASDAQ: ILMN) plans to buy Grail Inc, adding uncertainty to whether regulators will wrap up before the deal expires. As first reported by Reuters, the Commission is waiting on Illumina to fulfill a data request.

News for Illumina Stock (ILMN)